Lineage Cell Therapeutics Inc. (NYSE American: LCTX) Starts Presentation at The LD 500
Lineage Cell Therapeutics Inc. (NYSE American: LCTX) is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's clinical programs are in markets with billion-dollar opportunities and include three allogeneic ("off-the-shelf") product candidates: (i) OpRegen(R), a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in…